

Contact: Anette Breindl, Ph.D.
Atkins + Associates
(858) 860-0266 x. 105
abreindl@irpr.com

FOR IMMEDIATE RELEASE

**MAXCYTE'S CELL LOADING TECHNOLOGY ELIMINATES MAJOR
GENE TRANSFER SAFETY CONCERN**

*Company Demonstrates Exceptional Cell Transfection Rates at American Society of Gene
Therapy Annual Meeting*

Rockville, MD – June 5, 2002 – Gene therapy has experienced severe ups and downs over the past few years, but the biotechnology industry continues to develop innovations to overcome the roadblocks to treating disease by modifying or correcting gene expression. The primary issues researchers are addressing include improving patient safety and the efficiency of therapeutic gene transfer. Companies are racing to develop technologies to reduce the risk of immune response complications that have been a problem in previous clinical trials, and to transfect new cell types in order to broaden the potential applications for gene transfer. MaxCyte, Inc. has developed a technology that furthers both of these goals.

MaxCyte's continuous flow cell loading technology is a reinvention of static electroporation. The *ex vivo*, customizable MaxCyte GT™ system uses precisely designed electrical pulses to briefly make human and animal cell walls permeable, allowing DNA to be inserted into cells without using a viral vector or protein carrier. By regulating the properties of the electric field, the technology can transfect high volumes of cells with a wide range of differently sized molecules with unmatched efficiency. MaxCyte's closed, sterile system has many applications in gene and cell-based therapeutics, and the company will be presenting new scientific data demonstrating its versatility at the annual meeting of the American Society of Gene Therapy (ASGT) in Boston, June 5-9.

“MaxCyte's technology addresses many of the issues we've been grappling with and I think it has the potential to greatly affect the field of gene therapy,” said Dr. Malcolm Brenner, director,

Center for Cell and Gene Therapy at Baylor College of Medicine, and president of ASGT. “We look forward to using MaxCyte’s gene transfer technology in a clinical trial that we hope will start later this year.”

“MaxCyte’s ability to load any molecule into any cell offers a safe, fast, and effective solution to gene transfer therapeutics,” said Douglas Doerfler, president and CEO of MaxCyte. “MaxCyte’s technology is able to resolve several key issues around patient safety in gene therapy, which we believe could be a real turning point for the industry. We hope our research will help open new avenues to solve severe and chronic infections, cancer, cardiovascular disease and genetic disorders, and have an equally important impact on the economics of gene administration.”

At the ASGT meeting, MaxCyte’s Vice President for Clinical Development, Dr. Joseph Fratantoni, and Director of Gene Therapy, Dr. Linda Liu, will present three posters detailing how the MaxCyte GT system has successfully demonstrated that it can efficiently load cells with DNA for therapeutic gene transfer and gene correction without the use of viral vectors. MaxCyte has also succeeded in scaling-up cell loading speed and volume levels that could make this technology suitable for use at a patient’s bedside. MaxCyte’s data demonstrates the researchers were able to transfect cell types that previously have been hard to permeate with available vectors. In a study with the Baylor College of Medicine, a greater than 75% transfection rate was achieved when plasmid DNA was inserted into chronic lymphocytic leukemia B-cells. Eighty percent of the cells were viable and MaxCyte’s production rate of several million cells per second provided increased efficiency and volume capabilities, which substantially reduced the amount of labor and time involved. Additionally, the transfected cells expressed the transgenes for a sufficient amount of time to be functionally effective.

MaxCyte Poster Presentations at ASGT – <http://www.apnet.com/asgt/>

- Efficient Non-viral Transfection of CLL-B cells with Human CD40 Ligand, Abstract # 354
- A Novel Approach for *ex vivo* Non-viral Gene Delivery, Abstract #1025
- Single Base Gene Conversion by Single Strand DNA Oligo Delivered by Electroporation, Abstract #1026

About MaxCyte

MaxCyte, Inc. is a clinical stage biotechnology company improving therapeutic gene transfer, identifying more targeted ways to deliver drugs, and accelerating the drug discovery process by developing and using new cell loading technologies. The MaxCyte GT™ flow electroporation system brings individualized cell loading to the clinic for the first time. MaxCyte can load large volumes of any molecule, including drugs, nucleic acids and proteins, into any cell rapidly enough to enable on-site patient treatment. MaxCyte's biotechnology and pharmaceutical partners gain a competitive edge by using its customized cell loading technology for therapeutic and R&D applications. Therapeutic applications include non-viral gene delivery and drug delivery via platelets and blood cells, while drug discovery applications include high throughput target validation and *in vivo* biological assays for gene expression studies. MaxCyte's pipeline includes one therapeutic in Phase I clinical trials and therapeutics in preclinical development. MaxCyte is majority owned by Entremed, Inc. For more information, visit <http://www.maxcyte.com>.

About Entremed

Entremed, Inc. (NASDAQ: ENMD), The Angiogenesis Company®, is a clinical-stage biopharmaceutical company developing angiogenesis therapeutics that inhibit abnormal blood vessel growth associated with a broad range of diseases such as cancer, blindness and atherosclerosis. The company's strategy is to accelerate development of its core technologies through collaborations and sponsored research programs with pharmaceutical and biotechnology companies, universities and government laboratories. Entremed has three drug candidates in over 15 clinical trials, as well as a rich pipeline of new proteins, genes and small molecules under development and in preclinical studies. For further information, visit Entremed's web site at www.entremed.com.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

###